Primary synovial sarcoma of the kidney is a rare tumor that is difficult to diagnose. We present one case that was not diagnosed through fine needle aspiration, requiring a morphologic and immunohistochemical analysis of the incision biopsy. Since the tumor was surgically unresectable, chemotherapy was employed previously to definitive radical surgery.
INTRODUCTION
The synovial sarcoma is an uncommon tumor, representing approximately 6 to 10% of the primary sarcomas of soft tissues. Recently, rare primary cases were described in the kidney (1) (2) (3) . Signs and symptoms are similar to any primary renal tumor. Unspecific preoperative findings, associated with its rarity, prevent its early diagnosis.
CASE REPORT
Male, 27-year old patient, presenting gross hematuria and large abdominal mass. The abdominal computed tomography showed a large retroperitoneal mass, radiologically consistent with malignant neoplasia ( Figure-1 ). Aspiration puncture of the lesion was performed with fine needle, diagnosing small cell malignant neoplasia (Figure-2) .
During staging, no distant lesions were observed. Due to the large tumor volume, an option was made to performing adjuvant chemotherapy. A chemotherapy protocol for Wilms' tumor was started, with actinomycin 50 µg/Kg and vincristine 0.04 mg/ Kg, for 4 cycles, obtaining minimal response, with the mass remaining unresectable.
Open biopsy of the lesion was indicated, aiming a better subtyping of the neoplasia. Histopathological examination revealed a malignant neoplasia constituted by 2 distinct cell populations, one consisting of small cells with round hyperchromatic nu- With the considerable reduction of the tumor (approximately 50%), radical nephrectomy by right thoracolaparotomy was indicated, with partial exeresis of diaphragm and ascending colon being necessary. No macroscopically involved lymph nodes were found intraoperatively.
Histopathological examination of the surgical specimen revealed an encapsulated tumoral mass measuring 21 x 15 x 9 cm, weighting 1628 g, with extensive areas of necrosis and hemorrhage. The adrenal gland, ureter or renal vein were not involved, and the lymph node analysis was negative for neoplasia. Patient has been followed for 1 year with no signs of recurrence.
DISCUSSION
Primary synovial sarcoma of the kidney is a type of renal sarcoma. Leiomyosarcoma represents 40 -60% of the described renal sarcomas, followed by rhabdomyosarcoma, histiosarcoma, chondrosarcoma and osteosarcoma, liposarcoma, angiosarcoma and hemangiopericytoma (1-3). Only 20 cases were reported in the literature. It affects young individuals, of both genders, between 20 and 50 years, presenting a clinical picture that is similar to renal tumors in general (1). There is no clinical or imaging characteristic that can indicate the diagnosis (1-5). Differential diagnosis with other renal tumors constituted by spindle or round cells is difficult, requiring immunohistochemical studies or molecular analysis. Among the differential diagnoses, are especially the mesoblastic nephroma and adult neuroectodermal tumor (PNET), in addition to adult Wilms' tumor and fibrosarcoma.
The mesoblastic nephroma is usually immunoreactive for actin and negative for epithelial markers. The synovial sarcoma presents immunoreaction for epithelial markers such as cytokeratin and epithelial membrane antigen, generally with focal distribution. The proteins CD99 and Bcl-2 were detected in 70% and 100% of cases, respectively. PNET tumors are immunoreactive to CD99 and generally negative for Bcl-2 and epithelial membrane antigen. However, since there is not a specific immunohistochemical marker for the synovial sarcoma, definitive diagno- sis can be achieved only by identifying the characteristic T chromosomal translocation (X; 18), through reverse transcriptase polymerase chain reaction with fluorescence in situ hybridization (FISH) (1-3) . In the present case, since we could not count on chromosomal analysis, diagnosis was established based on conventional morphologic microscopic analysis and immunohistochemistry.
In one research on 17 cases (1), 4 presented lung, liver or bone metastases and evolved to death, 2 presented pelvic recurrence.
Adjuvant and neoadjuvant chemotherapy, using high doses of doxorubicin, cisplatin and iphosphamide (14 g/m 2 ) performed in 14 patients without initial metastatic disease, rendered 93% of patients disease-free in a mean follow-up of 37 months (6 to 85 months) (5) .
The base for chemotherapy in such cases is the iphosphamide, usually reducing the tumor volume by 50% or more (3, 5) . There is no consensus in the literature concerning the standard chemotherapy scheme. In this case, the scheme consisting in iphosphamide and adriamycin reduced approximately 50% of the tumor, enabling its surgical resection.
